Ican Consult & Counseling Center Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 505 N Main St, Charleston, MO 63834 Phone: 573-262-8515 |
Saint Francis Clinic Charleston Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 112 W Commercial St, Charleston, MO 63834 Phone: 573-683-4010 Fax: 573-683-2167 |
Saint Francis Clinic Charleston Social Worker - Clinical Medicare: Medicare Enrolled Practice Location: 112 W Commercial St, Charleston, MO 63834 Phone: 573-683-4010 Fax: 573-683-2167 |
News Archive
High Intensity Focused Ultrasound (HIFU) treatment is a non-invasive method that removes unhealthy tissues and tumors by delivering high intensity ultrasound waves from outside of the body to the lesion. It does only a minimal damage to the normal tissues around the lesion and allows fast recovery of a patient which is why this innovative treatment has been called as the "ultrasound of the next generation."
In a small clinical study, researchers administered a new method for treating chronic wounds using a novel ultrasound applicator that can be worn like a band-aid. The applicator delivers low-frequency, low-intensity ultrasound directly to wounds, and was found to significantly accelerate healing in five patients with venous ulcers.
Noting the release of the Institute of Medicine PEPFAR evaluation and an October 2012 report of the Data Working Group of PEPFAR's Scientific Advisory Board, Mead Over and Rachel Silverman of the Center for Global Development propose in the group's "Global Health Policy" blog "four recommendations where there seems to be agreement and feasible opportunities to improve PEPFAR's collection, utilization, and dissemination of data and knowledge."
A team led by a Canadian researcher has discovered a process by which a small protein acts directly within muscles to increase the body's metabolism to burn fat while simultaneously suppressing appetite.
Isotretinoin (also known as Accutane) is a drug used to treat severe acne, but it can cause birth defects when taken by pregnant women. Because of these risks, the U.S. Food and Drug Administration and Roche Pharmaceuticals (Accutane's manufacturer) developed a voluntary pregnancy prevention program (PPP) in 1988 to try and prevent conception in women taking the drug.
› Verified 7 days ago